Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digestmore is a commercial digestive aid formulation developed and marketed by Moral Pharmaceuticals Pvt Ltd, an Indian pharmaceutical company. It is primarily indicated for the management of indigestion, dyspepsia, and flatulence. The product is typically formulated as a combination of digestive enzymes, most commonly fungal diastase and pepsin. Fungal diastase, an alpha-amylase derived from fungi such as *Aspergillus oryzae*, facilitates the hydrolysis of starch into maltose and other simpler sugars, thereby aiding carbohydrate digestion. Pepsin is a proteolytic enzyme that breaks down complex dietary proteins into smaller peptides and amino acids in the stomach's acidic environment. By supplementing these endogenous enzymes, Digestmore assists in the efficient breakdown of nutrients, helping to alleviate symptoms of bloating and gastric discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Digestmore.